For HCPs Only
Recent Clinical Updates
Loading latest clinical updates
All Authors
SI

HCP Connect Clinical Author

Dr. Sanjay Iyer

Gastroenterology

Credentials: MBBS, MD (General Medicine), DM (Gastroenterology)

Specialty

Gastroenterology

Clinical Updates

11

Experience

10 Years

Author Biography

About Dr. Sanjay Iyer

Dr. Sanjay Iyer is a gastroenterologist with a decade of clinical experience. He holds a DM in Gastroenterology after an MD in General Medicine and is trained in diagnostic and therapeutic endoscopy. His special interests are inflammatory bowel disease and hepatology. He writes to help physicians apply the latest luminal and liver guidelines with confidence.

Published Work

Recent Clinical Updates

11 articles

Gastroenterology

FDA Approves bulevirtide for chronic HDV: 48% combined response at Week 48

bulevirtide hepatitis delta virus: FDA approves Hepcludex for chronic HDV on 5/22/2026 after MYR301 showed 48% combined response at Week 48.

Sep 1, 2026|5 min read|Via DailyMed

Gastroenterology

AGA Updates Ulcerative Colitis Guidelines: Recommends Multiple Therapies

AGA living guideline (Dec 2024): recommendations for infliximab, golimumab, vedolizumab, upadacitinib, mirikizumab and other advanced therapies in moderate-to-severe ulcerative col...

Aug 28, 2026|5 min read|Via PubMed

Gastroenterology

Resmetirom (REZDIFFRA) Approved for Adults with Noncirrhotic MASH (F2–F3) After Month 12 Histology Gains

Resmetirom (REZDIFFRA) approved for adults with noncirrhotic MASH (F2–F3); Month 12 histology showed resolution and fibrosis improvement. resmetirom metabolic dysfunction-associate...

Aug 27, 2026|7 min read|Via PubMed

Gastroenterology

FDA Requires Boxed Warning for Upadacitinib (Rinvoq): Heart Events, Cancer, Clots, Death

upadacitinib ulcerative colitis: FDA requires Boxed Warning updates for JAK inhibitors listing heart events, cancer, blood clots, and death; dosing per label included.

Aug 17, 2026|5 min read|Via FDA

Gastroenterology

FDA Approves Linerixibat for PBC Pruritus: -0.72 WI-NRS in GLISTEN

Linerixibat (Lynavoy) approved for PBC pruritus after GLISTEN showed adjusted WI-NRS difference -0.72 vs placebo; diarrhea and LFT changes were notable adverse events.

Jul 11, 2026|6 min read|Via PubMed

Healthcare Business

AI Prior Auth: 30% Reimbursement Risk for 6 States

New Medicare pilot program introduces AI-powered prior authorization, potentially reducing reimbursement for certain medical procedures in 6 states, sparking concerns among healthc...

Apr 16, 2026|8 min read|Via Healthcare Dive

Medical Research

Uncover Lipid Metabolism Secrets to Diagnose MASLD

Discover how lipid droplets in hepatocytes contribute to hepatic steatosis in MASLD, a key to accurate diagnosis and treatment of the condition.

Apr 12, 2026|12 min read|Via Journal of Clinical Investigation

Digital Health

Clear Digital Leadership: Boost NHS Transformation

Discover how clear digital leadership can accelerate NHS transformation and reduce duplication, improving healthcare outcomes and efficiency.

Apr 5, 2026|3 min read|Via Digital Health News

Medical Research

COVID-19 Shot Guidance: What to Expect

Get the latest on potential changes to COVID-19, hepatitis B, and chickenpox vaccine recommendations and their impact on your practice.

Apr 3, 2026|6 min read|Via Medical Xpress

Health Information

Cut Vaping Costs with Longer-Lasting Devices

Discover how high-puff vapes can reduce overhead costs and provide better value for patients who vape, with devices delivering up to 60,000 puffs.

Mar 31, 2026|6 min read|Via Health Soothe

Medical Research

Cut PMADs by 20% with Proper Screenings

Improve maternal mental health outcomes by identifying gaps in perinatal mood and anxiety disorder screenings and support systems for new mothers.

Mar 25, 2026|3 min read|Via Medical Xpress